268 related articles for article (PubMed ID: 34926276)
1. Why Single-Cell Sequencing Has Promise in MDS.
Zhang X; Grimes HL
Front Oncol; 2021; 11():769753. PubMed ID: 34926276
[TBL] [Abstract][Full Text] [Related]
2. Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution.
Ainciburu M; Ezponda T; Berastegui N; Alfonso-Pierola A; Vilas-Zornoza A; San Martin-Uriz P; Alignani D; Lamo-Espinosa J; San-Julian M; Jiménez-Solas T; Lopez F; Muntion S; Sanchez-Guijo F; Molero A; Montoro J; Serrano G; Diaz-Mazkiaran A; Lasaga M; Gomez-Cabrero D; Diez-Campelo M; Valcarcel D; Hernaez M; Romero JP; Prosper F
Elife; 2023 Jan; 12():. PubMed ID: 36629404
[TBL] [Abstract][Full Text] [Related]
3. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
4. Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS.
Buck MC; Bast L; Hecker JS; Rivière J; Rothenberg-Thurley M; Vogel L; Wang D; Andrä I; Theis FJ; Bassermann F; Metzeler KH; Oostendorp RAJ; Marr C; Götze KS
iScience; 2023 Aug; 26(8):107328. PubMed ID: 37520699
[TBL] [Abstract][Full Text] [Related]
5. Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis.
Matos A; Magalhães SMM; Rauh MJ
Adv Exp Med Biol; 2021; 1326():1-10. PubMed ID: 33385175
[TBL] [Abstract][Full Text] [Related]
6. Emerging Insights into Molecular Mechanisms of Inflammation in Myelodysplastic Syndromes.
Vallelonga V; Gandolfi F; Ficara F; Della Porta MG; Ghisletti S
Biomedicines; 2023 Sep; 11(10):. PubMed ID: 37892987
[TBL] [Abstract][Full Text] [Related]
7. Stem Cells in the Myelodysplastic Syndromes.
Zhan D; Park CY
Front Aging; 2021; 2():719010. PubMed ID: 35822030
[TBL] [Abstract][Full Text] [Related]
8. Myelodysplastic syndromes are multiclonal diseases derived from hematopoietic stem and progenitor cells.
Luo B; Dong F; Qin T; Zhang Q; Bai H; Wang J; Jia Y; Ma S; Jiang E; Cheng T; Xiao Z; Ema H
Exp Hematol Oncol; 2022 May; 11(1):28. PubMed ID: 35578364
[TBL] [Abstract][Full Text] [Related]
9. Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine.
Chanias I; Stojkov K; Stehle GT; Daskalakis M; Simeunovic H; Njue LM; Schnegg-Kaufmann AS; Porret NA; Allam R; Rao TN; Benz R; Ruefer A; Schmidt A; Adler M; Rovo A; Balabanov S; Stuessi G; Bacher U; Bonadies N; On Behalf Of The Swiss Mds Study Group
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34209457
[TBL] [Abstract][Full Text] [Related]
10. Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.
Chesnais V; Arcangeli ML; Delette C; Rousseau A; Guermouche H; Lefevre C; Bondu S; Diop M; Cheok M; Chapuis N; Legros L; Raynaud S; Willems L; Bouscary D; Lauret E; Bernard OA; Kosmider O; Pflumio F; Fontenay M
Blood; 2017 Jan; 129(4):484-496. PubMed ID: 27856460
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology and Pathogenesis of Myelodysplastic Syndrome.
Rotter LK; Shimony S; Ling K; Chen E; Shallis RM; Zeidan AM; Stahl M
Cancer J; 2023 May-Jun 01; 29(3):111-121. PubMed ID: 37195766
[TBL] [Abstract][Full Text] [Related]
12. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.
Steensma DP; Bejar R; Jaiswal S; Lindsley RC; Sekeres MA; Hasserjian RP; Ebert BL
Blood; 2015 Jul; 126(1):9-16. PubMed ID: 25931582
[TBL] [Abstract][Full Text] [Related]
13. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.
Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F
Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566
[TBL] [Abstract][Full Text] [Related]
14. Targeting inflammation in lower-risk MDS.
Gonzalez-Lugo JD; Verma A
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):382-387. PubMed ID: 36485128
[TBL] [Abstract][Full Text] [Related]
15. Myelodysplastic syndrome hematopoietic stem cell.
Li J
Int J Cancer; 2013 Aug; 133(3):525-33. PubMed ID: 23047726
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications.
Simoni Y; Chapuis N
Diagnostics (Basel); 2022 Jul; 12(7):. PubMed ID: 35885563
[TBL] [Abstract][Full Text] [Related]
17. How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?
Steensma DP
Best Pract Res Clin Haematol; 2021 Dec; 34(4):101327. PubMed ID: 34865699
[TBL] [Abstract][Full Text] [Related]
18. Aging, hematopoiesis, and the myelodysplastic syndromes.
Chung SS; Park CY
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):73-78. PubMed ID: 29222239
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow macrophages are involved in the ineffective hematopoiesis of myelodysplastic syndromes.
Xing T; Yao WL; Zhao HY; Wang J; Zhang YY; Lv M; Xu LP; Zhang XH; Huang XJ; Kong Y
J Cell Physiol; 2024 Feb; 239(2):e31129. PubMed ID: 38192063
[TBL] [Abstract][Full Text] [Related]
20. What Clonal Hematopoiesis Can Teach Us About MDS.
Chan ICC; Wiley BJ; Bolton KL
Front Oncol; 2022; 12():794021. PubMed ID: 35211401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
